Add BrightSurf on Google Email

Mayo Clinic


Mayo Clinic finds upper, lower body gain weight differently

Researchers found that increased abdominal fat increases the risk of metabolic disease, while fat gain in the thighs lowers the risk. The study challenges the concept that the number of fat cells remains stable in adults and suggests a potential protective effect of lower-body fat cells.

SourceMayo Clinic·JournalProceedings of the National Academy of Sciences·DateOct 4, 2010

Mayo collaboration finds source of breast drug side effect

A Mayo Clinic collaboration identified four genetic variants on chromosome 14 associated with aromatase inhibitor-induced arthritis. These findings provide a new clue for identifying women at risk and developing treatments, allowing more women to take lifesaving breast cancer therapy.

SourceMayo Clinic·JournalJournal of Clinical Oncology·DateSep 27, 2010

4 possible risk factors for ovarian cancer found

A consortium of cancer researchers has identified four chromosome locations with genetic changes that may alter a woman's risk of developing ovarian cancer. These findings are based on a large genome-wide association study and could lead to individualized risk assessments for ovarian cancer.

SourceMayo Clinic·JournalNature Genetics·DateSep 19, 2010

Mayo's 'smart' adult stem cells repair hearts

Researchers demonstrate that rationally guided human adult stem cells can effectively heal, repair, and regenerate damaged heart tissue. The study shows improved heart function recovery, reduced scars, and increased survival rate in mouse models with heart failure.

SourceMayo Clinic·JournalJournal of the American College of Cardiology·DateAug 16, 2010

Results from a study testing methylphenidate for cancer-related fatigue

Researchers tested methylphenidate, a psychostimulant medication, to treat cancer-related fatigue. While the study found no significant difference between treatment and placebo groups, there was a trend of improved satisfaction with treatment among patients receiving methylphenidate, particularly those with stage III/IV cancer.

SourceMayo Clinic·JournalJournal of Clinical Oncology·DateJun 2, 2010

Study identifies promising treatment for aggressive lymphoma

A study published in the American Society of Clinical Oncology annual meeting showed that lenalidomide significantly improved response rates and complete remission in patients with transformed lymphoma. Patients treated with lenalidomide had a remarkable response rate, with some experiencing complete remission for over a year.

SourceMayo Clinic·JournalJournal of Clinical Oncology·DateMay 26, 2010